Parkinson's Disease: Is it possible to slow its progression?
Published Aug 31, 2024 • By Somya Pokharna
Parkinson’s disease is a progressive neurodegenerative disorder that primarily affects movement. As the disease progresses, symptoms worsen, heavily impacting the quality of life. However, recent research has provided hope that slowing the progression of Parkinson's disease might be achievable through a combination of therapies, lifestyle changes, and emerging treatments.
So, how does Parkinson’s disease progress, and what are the daily habits, therapies and treatments that may help slow it down?
We cover all the details in this article!
What causes Parkinson's disease to progress?
Parkinson's disease is characterized by the degeneration of dopamine-producing (dopaminergic) neurons in a specific region of the brain called the substantia nigra. This loss of dopamine, a neurotransmitter essential for coordinating movement, leads to the hallmark symptoms of Parkinson's disease—tremors, rigidity, bradykinesia (slowness of movement), and postural instability.
The exact cause of neuron death in Parkinson’s disease remains unclear, but several factors are believed to contribute, including genetic mutations, environmental toxins, and the accumulation of misfolded proteins, particularly a harmful protein called alpha-synuclein. Recent research from Johns Hopkins has found that alpha-synuclein triggers processes that kill brain cells, indicating that targeting this protein could be the key to slowing Parkinson's disease.
How do lifestyle changes slow Parkinson's disease progression?
Lifestyle changes play a significant role in slowing Parkinson’s disease progression:
Exercise
One of the most promising approaches to slowing Parkinson’s disease progression is exercise. Multiple studies show that regular physical activity can significantly improve motor function and may even modify the course of the disease. It can enhance neuroplasticity—the brain’s ability to reorganize itself by forming new neural connections. This process may help compensate for the loss of dopaminergic neurons and improve motor control. Moreover, exercise has been shown to increase the production of brain-derived neurotrophic factor (BDNF), a protein that supports the survival and growth of neurons, which could potentially slow disease progression.
High-intensity exercises, such as brisk walking, cycling, and strength training, are particularly beneficial. These activities not only improve physical symptoms, but also have the potential to stabilize or reduce the amount of medication needed to manage the disease. However, it is extremely important to always consult a healthcare provider before making any changes to your medication regimen.
The benefits of exercise are not limited to those who can engage in high-intensity workouts. Even low-intensity activities, such as walking or gardening, have been shown to offer significant benefits for people with Parkinson’s disease. The key is consistency and tailoring the exercise regimen to the patient’s abilities and needs, ideally under the guidance of healthcare professionals.
Diet
Diet has also been shown to influence the course of the disease. The Mediterranean diet, rich in fruits, vegetables, whole grains, and healthy fats, has been associated with slower cognitive decline in Parkinson’s disease patients. This diet is thought to reduce inflammation and oxidative stress, both of which contribute to neurodegeneration.
Cognitive engagement
Engaging in mentally stimulating activities, such as reading, puzzles, and social interaction, has been shown to improve cognitive function and may help delay the onset of dementia, a common complication in later stages of Parkinson’s disease.
What is the role of GLP-1 receptor agonists (diabetes drugs) in slowing the progression of Parkinson's disease?
Recent research has also explored the potential of certain diabetes medications, specifically GLP-1 receptor agonists, in slowing Parkinson's disease progression. These drugs, originally designed to manage blood sugar levels in diabetes, have shown neuroprotective effects in preclinical studies. They work by reducing inflammation and oxidative stress in the brain, both of which are thought to contribute to the neurodegeneration seen in Parkinson's disease. Examples of these GLP-1 receptor agonists include:
- Exenatide (Byetta, Bydureon)
- Liraglutide (Victoza)
- Dulaglutide (Trulicity)
- Semaglutide (Ozempic, Rybelsus)
- Lixisenatide (Adlyxin)
Exenatide has been the subject of clinical trials for Parkinson’s disease with some promising early results, showing that patients treated with it experienced slower progression of motor symptoms compared to those who did not receive the drug.
However, while these findings are encouraging, more extensive trials are needed to confirm these benefits and determine the long-term effects of GLP-1 medications in Parkinson’s disease patients. Make sure to consult your healthcare provider before adding any new medication to your regimen.
Can targeting alpha-synuclein slow the progression of Parkinson's disease?
The protein alpha-synuclein aggregates abnormally in the brains of Parkinson’s disease patients. These aggregates, known as Lewy bodies, are toxic to neurons and are thought to play a key role in the progression of Parkinson's disease.
Recent research has found new ways to target alpha-synuclein. For instance, researchers at Johns Hopkins have discovered that pathological alpha-synuclein can trigger excessive protein synthesis in neurons, leading to cellular stress and eventual cell death. By targeting the molecular pathways involved in this process, researchers hope to develop treatments that can slow or even stop the progression of Parkinson's disease.
One promising approach involves using antibody infusions to neutralize alpha-synuclein. Early-stage clinical trials have shown that this method might slow the build-up of the protein and delay the progression of motor symptoms. While still experimental, this approach is a promising new direction in Parkinson’s disease research.
Given that Parkinson’s disease is very complex and varies widely among individuals, personalized care is fundamental. What works for one patient may not work for another. Therefore, treatment plans should be tailored person-to-person, featuring a combination of medication, exercise, diet, and other therapies. It is essential to follow-up regularly with healthcare providers to monitor disease progression and adjust treatment as needed.
In the future, advanced biomarkers and genetic testing may help doctors predict how Parkinson's disease will progress in each patient, allowing for more precise treatments. Until then, combining standard medical care with lifestyle changes is the best way to slow down the disease and improve quality of life.
Was this article helpful to you?
Give it a “Like” and share your thoughts and questions with the community in the comments below!
Take care!
Sources:
A treatment for diabetes may slow the progression of Parkinson's disease — Bordeaux Neurocampus
Can Exercise Slow Parkinson's Disease Progression? with Daniel Corcos, PhD: Research — Feinberg School of Medicine
Can Progression of Parkinson Disease Be Slowed? — American Journal of Managed Care
Can We Put the Brakes on Parkinson’s Progression? — Parkinson's Foundation
Deep brain stimulation in early-stage Parkinson disease — NIH
Early-stage Parkinson’s: Regular exercise may slow progression — Medical News Today
Fighting Parkinson's Disease with Exercise and Diet — Johns Hopkins Medicine
Five exercises that may help slow the progression of Parkinson’s disease — St Josephs/Candler
GLP—1 medications may slow progression of Parkinson’s symptoms — UCLA Health
Newly Diagnosed with Parkinson’s Disease? Here’s What You Need to Know — Temple Health
Parkinson's disease progression slowed by antibody infusions — New Scientist
Parkinson's Disease: Study Finds Intense Exercise May Ease Symptoms — Healthline
Therapies to Slow, Stop, or Reverse Parkinson’s Disease — NIH